Thematics Asset Management Raises Stock Position in DexCom, Inc. $DXCM

Thematics Asset Management boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 22.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 315,392 shares of the medical device company’s stock after purchasing an additional 58,663 shares during the period. Thematics Asset Management owned approximately 0.08% of DexCom worth $21,538,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC raised its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Private Trust Co. NA raised its stake in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares during the period. Farther Finance Advisors LLC raised its stake in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company’s stock worth $209,000 after purchasing an additional 702 shares during the period. Dynamic Advisor Solutions LLC raised its stake in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company’s stock worth $357,000 after purchasing an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC raised its stake in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company’s stock worth $220,000 after purchasing an additional 2,909 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DXCM opened at $82.26 on Friday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm’s 50 day moving average price is $82.81 and its 200 day moving average price is $79.83. The company has a market cap of $32.26 billion, a P/E ratio of 57.13, a PEG ratio of 1.72 and a beta of 1.43. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm earned $0.43 EPS. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the sale, the executive vice president directly owned 106,689 shares of the company’s stock, valued at $9,494,254.11. This represents a 1.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,906 shares of company stock valued at $1,832,451 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Raymond James Financial lifted their target price on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Mizuho boosted their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $106.00 price target on shares of DexCom in a research note on Friday, August 1st. Finally, Morgan Stanley boosted their price target on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.